Tirzepatide, a dual GIP and GLP-1 receptor agonist, also known as a “twincretin,” was approved by the Food and Drug Administration (FDA) in May 2022 to treat T2DM and in 2023 for chronic weight management [61,62]. This evidence concerns the gene GIP and type 2 diabetes mellitus.